{"qas": [{"question": "The safety and efficacy of new drugs must be approved by what organization in the US?", "id": "571d2eafdd7acb1400e4c246", "answers": [{"text": "Food and Drug Administration", "answer_start": 74}], "is_impossible": false}, {"question": "What type of filing is used before beginning human trials?", "id": "571d2eafdd7acb1400e4c247", "answers": [{"text": "Investigational New Drug", "answer_start": 192}], "is_impossible": false}, {"question": "How many phases of human trials may be done after IND approval?", "id": "571d2eafdd7acb1400e4c248", "answers": [{"text": "three", "answer_start": 323}], "is_impossible": false}, {"question": "What type of application is filed after completing three phases of human trials?", "id": "571d2eafdd7acb1400e4c249", "answers": [{"text": "New Drug Application", "answer_start": 667}], "is_impossible": false}, {"question": "What type of risk assessment results in approving the drug to go on the market?", "id": "571d2eafdd7acb1400e4c24a", "answers": [{"text": "positive benefit-risk", "answer_start": 776}], "is_impossible": false}, {"plausible_answers": [{"text": "Food and Drug Administration", "answer_start": 74}], "question": "What organization in the US must approve the safety and efficacy of testing?", "id": "5ad39f27604f3c001a3fe941", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Investigational New Drug", "answer_start": 192}], "question": "What type of filing is used before beginning risk assessment?", "id": "5ad39f27604f3c001a3fe942", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "three", "answer_start": 323}], "question": "How many phases of human trials may be done after review?", "id": "5ad39f27604f3c001a3fe943", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "New Drug Application", "answer_start": 667}], "question": "What type of application is filed after completing three phases of products?", "id": "5ad39f27604f3c001a3fe944", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "positive benefit-risk", "answer_start": 776}], "question": "What type of risk assessment results in approving the drug to go on to studies?", "id": "5ad39f27604f3c001a3fe945", "answers": [], "is_impossible": true}], "context": "T\u1ea1i Hoa K\u1ef3, c\u00e1c s\u1ea3n ph\u1ea9m d\u01b0\u1ee3c ph\u1ea9m m\u1edbi ph\u1ea3i \u0111\u01b0\u1ee3c s\u1ef1 ch\u1ea5p thu\u1eadn c\u1ee7a <a0_0><b5_0> C\u1ee5c Qu\u1ea3n l\u00fd Th\u1ef1c ph\u1ea9m v\u00e0 D\u01b0\u1ee3c <b5_0/><a0_0/> (FDA) v\u00ec v\u1eeba an to\u00e0n v\u1eeba hi\u1ec7u qu\u1ea3. Qu\u00e1 tr\u00ecnh n\u00e0y th\u01b0\u1eddng li\u00ean quan \u0111\u1ebfn vi\u1ec7c g\u1eedi m\u1ed9t <a1_0><b6_0> Thu\u1ed1c m\u1edbi \u0111i\u1ec1u tra <b6_0/><a1_0/> n\u1ed9p \u0111\u01a1n v\u1edbi \u0111\u1ee7 d\u1eef li\u1ec7u ti\u1ec1n l\u00e2m s\u00e0ng \u0111\u1ec3 h\u1ed7 tr\u1ee3 ti\u1ebfn h\u00e0nh th\u1eed nghi\u1ec7m tr\u00ean ng\u01b0\u1eddi. Theo sau s\u1ef1 ch\u1ea5p thu\u1eadn c\u1ee7a IND, <a2_0><b7_0> s\u1ed1 ba <b7_0/><a2_0/> c\u00e1c giai \u0111o\u1ea1n th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng tr\u00ean ng\u01b0\u1eddi c\u00f3 th\u1ec3 ti\u1ebfn tri\u1ec3n nhanh h\u01a1n. Giai \u0111o\u1ea1n I th\u01b0\u1eddng nghi\u00ean c\u1ee9u \u0111\u1ed9c t\u00ednh b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng t\u00ecnh nguy\u1ec7n vi\u00ean kh\u1ecfe m\u1ea1nh. Giai \u0111o\u1ea1n II c\u00f3 th\u1ec3 bao g\u1ed3m d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc v\u00e0 li\u1ec1u d\u00f9ng \u1edf b\u1ec7nh nh\u00e2n, v\u00e0 Giai \u0111o\u1ea1n III l\u00e0 m\u1ed9t nghi\u00ean c\u1ee9u r\u1ea5t l\u1edbn v\u1ec1 hi\u1ec7u qu\u1ea3 trong d\u00e2n s\u1ed1 b\u1ec7nh nh\u00e2n d\u1ef1 \u0111\u1ecbnh. Sau khi ho\u00e0n th\u00e0nh th\u00e0nh c\u00f4ng th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n III, <a3_0><b8_0> \u0110\u01a1n thu\u1ed1c m\u1edbi <b8_0/><a3_0/> \u0111\u01b0\u1ee3c g\u1eedi cho FDA. FDA xem x\u00e9t d\u1eef li\u1ec7u v\u00e0 n\u1ebfu s\u1ea3n ph\u1ea9m \u0111\u01b0\u1ee3c xem l\u00e0 c\u00f3 <a4_0><b9_0> l\u1ee3i \u00edch t\u00edch c\u1ef1c <b9_0/><a4_0/> \u0111\u00e1nh gi\u00e1, ph\u00ea duy\u1ec7t \u0111\u1ec3 ti\u1ebfp th\u1ecb s\u1ea3n ph\u1ea9m t\u1ea1i Hoa K\u1ef3 \u0111\u01b0\u1ee3c c\u1ea5p."}